Neurologist, businessman, philanthropist, and father- Jorge Moll is the President-director of the D’Or Institute for Research and Education in Rio De Janeiro, Brazil, where he’s accumulated such accolades as the Research Fellow NIH award, as well as Stanford University’s Visiting Scholar Award. Check more info here on crunchbase.com. His studies of the human brain and cognition are largely focused on helping people with mental illnesses achieve better quality of life. This desire to help others with the unfair, unpredictable challenges of impaired brain function is something which he says is a huge motivator for him. Moll takes inspiration and input from a wide variety of sources on a daily basis- from scholars, to other scientists and researchers, even from students. In this way, he keeps communication open, allowing for exchange of ideas and allowing for those ideas to flourish in the light of others. He’s always got new and innovative theories regarding his area of study- and makes a point of not wasting any time putting those plans into effective action. Moll says that he either runs with an idea or ditches it for the next, better one-rather than sitting around mulling over which idea to choose. He remains prolific by keeping himself open to every opportunity that comes his way, and grasping at each and every possibility to see if it works. Moll is interested in the future of technology and the possibilities that it holds for the future as well- the topics of artificial intelligence and fabricated cognition are of particular interest to him, as well as the study of regenerative medicine and gene therapy- a method that could possibly fix many of the problems that he deals with in his research and improve life for millions upon millions of people. In addition to all of his scientific achievements, Moll prides himself in being a loving and caring father and role model for his children. Moll currently resides at his home in De Janeiro with his family.
It’s been recently announced on the news that JP Morgan, Berkshire Hathaway and e-commerce giant Amazon have announced they have a new system for getting healthcare that could cut out the “middleman” when it comes to consumer purchases. It’s a complex issue to explain since the layers of healthcare all have profits flowing from pharmaceutical companies, to drug retailers like CVS and Walgreens, healthcare providers and networks as well the insurance companies. But in wake of this announcement meany healthcare stocks took a big hit in the stock market, though Paul Mampilly, an expert at Banyan Hill Publishing warned this was coming. What Mampilly says is that Amazon’s entering the drug sale marketplace will cause healthcare stocks to drop way down, and when they reach a point that makes them look good to buy, investors may be eager to snatch them up. But the bad news is they’re not likely to ever rebound.
Paul Mampilly doesn’t simply tell his followers what they want to hear. He gives them real advice on how to find good stocks that he himself learned during his Wall Street career, and he’s not a broker at Banyan Hill; he’s an author who tells his audience how to build their own portfolio. Prior to joining Banyan Hill, he spent several years in the hedge fund industry and more than 10 years in big banking. He got his bachelor’s degree in economics and finance from Montclair State University, and his master’s from Fordham University. He began in banking as a researcher for Deutsche Bank in 1991 and moved up the ranks in the offices of ING, Sears, Banker’s Trust and others.
Paul Mampilly gained major recognition from Barron’s magazine in 2006 when he joined the team at Kinetics International Fund and helped raise client AUM from $6 billion to $25 billion. He was touted for pooling client investments in funds that brought upwards of 40% in annual returns. Paul Mampilly also invested $50 million in alternative funds during the 2008 Templeton Foundation competition and ended with $88 million despite the recession reaching its peak at that time. He also was an early investor in Netflix and Sarepta Therapeutics prior to their stock reaching incredible highs. Mampilly’s success enabled him to retire from the corporate life early, but he feels his work is just begun in informing his audience on how to make stock investing work for them.